Company intelligence / Profile preview

Pantarhei Bioscience

Ownership: Private
Development stage: Phase 1

Overview

The company develops patent-protected innovative medical uses of existing hormones and drugs. Their lead product Estetrol (E4) has shown antagonistic effects on breast tumor tissue.

Therapeutic areas: Women's HealthOncology
Modalities: Hormonesexisting moleculesdrugsbiologicals and combinations
Industry: Biotech

Drug pipeline

1 asset

autogene cevumeran

Phase 1

Indications: Advanced solid tumors, Melanoma, Non-small cell lung cancer, Triple-negative breast cancer, Renal cell carcinoma, Urothelial cancer, Colorectal cancer

Partnerships

Previously partnered with Estetra (sold shares)potential partnership with Merck/MSD (proposed)

Beyond the preview

Go deeper on Pantarhei Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pantarhei Bioscience.

Explore the full profile